A research analyst who sought to make quick money by taking advantage of insider information is in serious trouble. His attempt to avoid detection of his insider trades by using his mother’s account has come a cropper. He has now not only to refund his ill-gotten gains but also faces serious criminal charges
A mid-cap Pharma stock strongly recommended by Sanjoy Bhattacharyya & Saurabh Mukherjea is facing the ignominy of being declared a flop. Luckily, another “100 Bagger” Pharma stock is surging and bringing cheer to investors
It is astonishing but true that if Bill Ackman, one of the finest investing minds, had adopted the investment strategy followed by our local gurus, he would have been spared the crippling loss that he suffered this week owing to the failure of his all-time favourite stock
Investors have always had the lurking suspicion that some unscrupulous analysts may be indulging in the nefarious practice of pump n’ dump. This is now proved true in investigations carried out by the SEC. The shocking aspect is that even highly reputed research houses are party to this
Today, in the midst of the carnage, Saurabh Mukherjea had an “I told you so” expression on his face. He warns that there is more downside coming and that we should stay out. We need to listen attentively to his advice with all eyes and ears open
The stock market is like a jungle where you either perform or perish. Given the high stakes involved, the tolerance for non-performance is limited. Fund manager Prashant Jain has his back to the wall because his major contrarian bets have backfired and his schemes are under-performing. Investors are getting restless. Will he be able to turn the fortunes of the Fund around before it is too late?
The savage melt-down in the stock price of Linkedin, one of the most successful internet companies, has not only wiped out Rs. 71,000 crore ($11 Billion) of investors’ wealth in just one day, but is also a “trigger warning” that a massive crash is on the way say experts
Prof Sanjay Bakshi’s favourite stock which supposedly has an “impenetrable moat” around it has fallen off the cliff. Worse, the Company is being likened to Satyam and questions are being raised about the existence of a huge amount of cash on its books. What is the way out for its beleaguered investors?
Tracking Dolly Khanna’s favourite stocks is a pleasurable activity because these stocks have the salutary habit of achieving the targets that are set for them. Religare has now jumped into the fray and set a target price which the stock looks eager to meet
Top brass managements usually keep a stiff upper lip when confronted with negative reports of analysts about their companies. However, Kiran Mazumdar Shaw of Biocon has adopted a combative stance and is proactively trashing the negative reports as being “illogical” and based on “poor understanding” while lauding the ones that are favourable to the Company
Recent Comments